Molecular stratification of high-grade urothelial carcinoma by immunohistochemistry with its histomorphological and clinical correlation

Simple item page
dc.contributor.authorGupta, Gen_US
dc.contributor.authorGupta, Ren_US
dc.contributor.authorPasricha, Sen_US
dc.contributor.authorSharma, Aen_US
dc.contributor.authorDurga, Gen_US
dc.contributor.authorKamboj, Men_US
dc.contributor.authorTripathi, Ren_US
dc.contributor.authorMehta, A.en_US
dc.date.accessioned2023-08-10T07:32:57Z
dc.date.available2023-08-10T07:32:57Z
dc.date.issued2022-12
dc.description.abstractIntroduction: Urothelial carcinoma poses a significant cause of morbidity and mortality. The recent classification of Tumors of Urinary System by World Health Organization fourth edition) has elucidated its molecular subtypes and its associated prognostic significance. Methods: We used immunohistochemistry marker expression (CK5/6, CK20, CD44, EGFR) as a surrogate marker, to stratify 150 cases of high-grade urothelial carcinoma into the intrinsic molecular subtypes. A correlation was also done with immunohistochemical markers p53, p21, E-cadherin and Ki-67. Results: On subtyping, 47.3% cases were basal, 42.7% luminal and 10% remained unclassified. We did not find GATA3 useful for molecular stratification in our study. Muscle invasion was seen in 59% of basal and 31% of luminal subtype (P = 0.016). Squamous differentiation was most commonly associated with basal subtype (P < 0.001). EGFR expression was seen in 62% of basal and 38% of luminal subtype (P = 0.014), and thus can be used as an additional marker for molecular stratification. Overexpression of p53 was seen in 64% cases of muscle invasive and 36% of non-muscle invasive high-grade carcinomas (P < 0.0001). An inverse relationship was observed between p53 and p21 immunoexpression (r = –0.494) (P < .0001). The overall survival at 1- and 2-year interval was more in the luminal subtype, suggesting an early mortality in basal group, (P = 0.827), and at 6 years both the groups had almost similar results. Conclusion: High-grade urothelial carcinoma is challenging in terms of therapeutic strategy. Increased understanding of underlying molecular basis helps identifying targetable treatment options, and newer biomarkers will enhance predictive and prognostic stratification.en_US
dc.identifier.affiliationsDepartment of Pathology, Rajiv Gandhi Cancer Institute and Research Centre, Rohini, New Delhi, Indiaen_US
dc.identifier.affiliationsDepartment of Research, Rajiv Gandhi Cancer Institute and Research Centre, Rohini, New Delhi, Indiaen_US
dc.identifier.citationGupta G, Gupta R, Pasricha S, Sharma A, Durga G, Kamboj M, Tripathi R, Mehta A.. Molecular stratification of high-grade urothelial carcinoma by immunohistochemistry with its histomorphological and clinical correlation. Indian Journal of Pathology & Microbiology. 2022 Dec; 65(4): 832-838en_US
dc.identifier.issn0377-4929
dc.identifier.issn0974-5130
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/223353
dc.languageenen_US
dc.publisherWolters Kluwer - Medknowen_US
dc.relation.issuenumber4en_US
dc.relation.volume65en_US
dc.source.urihttps://doi.org/10.4103/ijpm.ijpm_95_21en_US
dc.subjectHigh-gradeen_US
dc.subjectimmunohistochemistryen_US
dc.subjectmolecular stratificationen_US
dc.subjecturothelial carcinomaen_US
dc.titleMolecular stratification of high-grade urothelial carcinoma by immunohistochemistry with its histomorphological and clinical correlationen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
IJPM2022v65n4p832.pdf
Size:
1.98 MB
Format:
Adobe Portable Document Format
Download
Collections
Indian Journal of Pathology & Microbiology